胃肠道间质瘤临床病理分级及基因分型的研究进展  

Advances in clinicopathological classification and genotyping of gastrointestinal stromal tumors

作　　者：白辰光[1] 马大烈[1] 

机构地区：[1]中国人民解放军第二军医大学附属长海医院病理科,上海市200433

出　　处：《世界华人消化杂志》2011年第14期1431-1435,共5页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.30972876~~

摘　　要：近年来,随着新的标志物的发现和基因突变检测的逐步开展,胃肠道间质瘤的病理诊断已不再是临床工作的难点,但是其生物学行为仍然难以预料,判断时需综合考虑肿瘤的大体,组织学形态和临床情况.现在应用最为广泛的肿瘤分级分期方案主要是美国国立卫生研究院的侵袭危险度分级方案(2008年修订版)和国际抗癌联盟的TNM肿瘤分期方案(2010版),分级分期指标涉及肿瘤大小、核分裂指数、肿瘤部位和肿瘤是否破裂等.胃肠道间质瘤分子基因学的深入研究显示,基因突变类型与肿瘤预后和伊马替尼(imatinib)反应性密切相关,但仍有待进一步细化.In recent years,the discovery of new markers and advances in mutation detection technologies have made it easy to diagnose gastrointestinal stromal tumor（GIST）.However,it is still difficult to predict the biological behavior of GIST.Currently,the most prevalent GIST classification systems,including the National Institutes of Health（NIH） consensus criteria for assigning risk to gastrointestinal stromal tumors（2008 Revision） and the International Union Against Cancer TNM classif ication of malignant tumors（2010 version）,are based on tumor size,mitotic rate,tumor location,and presence of a tumor rupture or not.Molecular genetic studies have shown that genotype of GIST is closely related to tumor prognosis and response to imatinib mesylate.

关 键 词：胃肠道间质瘤 分级 临床病理 基因表型 

分 类 号：R735[医药卫生—肿瘤]